TLDR:
Medical Microinstruments has secured $110 million in venture capital funding to support the commercial rollout of its Symani surgical robot system. The funding will be used to collect additional clinical evidence, establish new hospital partnerships, and expand into the U.S. and Asia Pacific region. The system, designed to mimic human hand dexterity on a smaller scale, is aimed at assisting in open soft-tissue procedures.
- Medical Microinstruments secures $110 million in series C funding for Symani surgical robot system
- Funding to be used for additional clinical evidence collection, new hospital partnerships, and U.S. and Asia Pacific expansion
Article Summary:
A tiny surgical robot, the Symani system by Medical Microinstruments, has received $110 million in venture capital funding to support its commercial rollout. The series C funding round was led by Fidelity Management & Research Company and included previous backers such as Deerfield Management and Wellington Partners.
The CEO of MMI, Mark Toland, emphasized the company’s confidence in a less invasive solution for open surgery with the smallest wristed microinstruments. The funds will be used to gather more clinical evidence for Symani, establish new hospital partnerships, and expand the system’s reach in the U.S. and Asia Pacific region.
Symani, with its two robotic arms, is designed to replicate human hand dexterity on a smaller scale, assisting in delicate procedures such as free flap reconstructions, lymphatic surgery, and trauma replantations. MMI predicts a significant increase in the market for Symani’s eligible microsurgical procedures by 2028.
